Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of "Hold" from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has received an average recommendation of "Hold" from the twenty ratings firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, nine have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $111.4444.

ZBH has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. UBS Group raised their target price on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a "sell" rating in a report on Friday, August 8th. Royal Bank Of Canada lifted their target price on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Robert W. Baird cut their price target on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Finally, Evercore ISI decreased their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares in the company, valued at $1,940,280. This represents a 4.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Monarch Capital Management Inc. raised its holdings in shares of Zimmer Biomet by 2.0% during the 2nd quarter. Monarch Capital Management Inc. now owns 35,028 shares of the medical equipment provider's stock valued at $3,201,000 after purchasing an additional 695 shares in the last quarter. State of Wyoming bought a new position in shares of Zimmer Biomet during the 2nd quarter valued at $124,000. CYBER HORNET ETFs LLC acquired a new position in Zimmer Biomet in the 2nd quarter valued at $50,000. FORA Capital LLC acquired a new position in Zimmer Biomet in the 2nd quarter valued at $2,307,000. Finally, Headlands Technologies LLC acquired a new position in Zimmer Biomet in the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock traded up $1.3780 on Monday, hitting $105.6880. The company had a trading volume of 1,844,246 shares, compared to its average volume of 2,066,551. The business has a 50-day simple moving average of $94.74 and a 200-day simple moving average of $99.30. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The company has a market cap of $20.94 billion, a PE ratio of 25.71, a PEG ratio of 2.02 and a beta of 0.68. Zimmer Biomet has a 52 week low of $89.22 and a 52 week high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The business had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business's revenue was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts expect that Zimmer Biomet will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, July 31st. Investors of record on Thursday, June 26th were paid a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.